Rationale Neurotensin-1 (NT1) receptor agonists have been proposed as putative antipsychotic drugs. Recently, brainpenetrating NT analogs produced by stability-enhancing modification of the smallest NT fragment, , have demonstrated antipsychotic-like efficacy after acute systemic injection in several preclinical animal tests predictive for antipsychotic efficacy. However, the evidence regarding the persistence versus tolerance of these effects after repeated administration is ambiguous. Previous studies have used compounds that nonselectively activated both NT1 and NT2 receptors or used continuous slow, central infusion of doses rather than daily acute administration, both factors which may have contributed to the ambiguity in the literature regarding the emergence of tolerance. Objectives To determine if tolerance develops to the antipsychotic-like effects of NT1 receptor agonists, we investigated the effects of subchronic daily systemic administration of PD149163, a brain-penetrating NT analog with selectivity for the NT1 receptor, on amphetamineinduced locomotor activation, a classic preclinical test of antipsychotic efficacy. Materials and methods Sprague-Dawley rats were pretreated with eight consecutive daily subcutaneous (SC) injections of PD149163 or saline. On the ninth day, rats received a pair of SC injections consisting of PD149163 or saline, followed by amphetamine (0.5 mg/kg) or saline.
Introduction
Neurotensin (NT) is a 13-amino acid neuropeptide that appears to be able to regulate the mesolimbic dopamine and other neurotransmitter systems implicated in psychosis Boules et al. 2007; Kinkead et al. 1999; Kinkead and Nemeroff 2004) . Administration of NT into the brain produces effects consistent with an antipsychotic drug (APD) (Feifel et al. 1997; Ervin and Nemeroff 1988) . Due to these findings, there has been considerable interest in developing NT agonists that, unlike NT itself, can resist enzymatic degradation in the periphery and penetrate the blood-brain barrier after systemic administration. One approach used has been to induce metabolically stabilizing modifications to the C-terminal hexapeptide, , which is the smallest fragment of the parent NT peptide to retain full biological activity (Boules et al. 2001 ). This approach has resulted in several small peptide NT analogs that produce central effects after systemic administration. One example is N-methyl-Arg(8),L-Lys(9), L-neo-Trp(11),tert-Leu(12) (NT69L) (Boules et al. 2001) . Acute systemic administration of NT69L produces many of the same effects produced by NT administered centrally, including hypothermia, antinociception, and APD-like behavioral effects such as antagonism of dopamine agonist-induced hyperlocomotion, climbing, disruption of prepulse inhibition of the startle reflex (PPI), and catalepsy induced by haloperidol (Boules et al. 2003; Boules et al. 2001) .
Effective antipsychotic treatment requires chronic administration; thus, it is important to investigate the effects of any putative APD after subchronic, in addition to acute, administration. While the acute effects of NT and NT analogs have been extensively investigated, less research has been conducted on the effects of NT agonists after repeated administration. Boules et al. (2003) studied the effects of NT69L administered systemically for up to five consecutive days and found that its ability to induce hypothermia, antinociception, and block haloperidol-induced catalepsy exhibited rapid tolerance, whereas its ability to antagonize amphetamine-and cocaine-induced hyperlocomotion and apomorphine-induced climbing persisted. Similarly, Hadden et al. (2005) , testing a different modified NT(8-13) peptide, KK28, also found that it continued to block amphetamineinduced hyperlocomotion after administration for five consecutive days. In contrast, Hertel et al. (2001 Hertel et al. ( , 2002 found that the APD-like reduction in spontaneous locomotor activity, antagonism of amphetamine-induced hyperlocomotion, and conditioned avoidance responding, produced by acute systemic administration of NT69L, exhibited tolerance after six consecutive, twice-daily systemic injections of this compound. Thus, the evidence of whether there is tolerance to the acute APD-like effects of NT69L is ambiguous.
Modulation of dopamine function by NT and NT analogs plays an important role in their APD-like behavioral effects. For example, Wang et al. (2004) found that pretreatment with NT69L for 5 days produced tolerance to some aspects of the modulation of dopamine function produced by NT69L but not others. The authors suggested that distinct NT receptors may be involved in the effects exerted by NT69L and other NT analogs on dopamine function. The same group subsequently demonstrated that systemic pretreatment with NT69L for five consecutive days induced downregulation of NT1 but not NT2 receptors in the brain (Wang et al. 2005) , supporting the possibility that distinct NT receptor types play different roles in the changes seen in the APD-like behavioral effects of NT and NT analogs with prolonged exposure to NT analogs. Thus, the ambiguity regarding the question of tolerance reported in studies using NT69L may be due to its nonselective affinity for both the NT1 and NT2 receptors (see the "Discussion" section; Wang et al. 2005) .
Lys(CH2NH)Lys-Pro-Trp-tLe-Leu-OET (PD149163) is another NT analog produced by chemical modification of to enhance its stability after systemic administration (Wustrow et al. 1995) . Unlike NT69L, PD149163 has selective affinity for the NT1 receptor (Petrie et al. 2004) . The NT1 receptor is the NT receptor most strongly implicated in mediating the APD-like effects seen with acute administration of NT and NT analogs such as NT69L and PD149163. Acute systemic administration of PD149163 has produced robust APD-like effects in a number of preclinical predictive tests of APD efficacy including facilitation of PPI (Feifel et al. 1999 (Feifel et al. , 2003a (Feifel et al. , b, 2004 . In a recent study, our laboratory found that the APD-like facilitation of the naturally low PPI in Brattleboro rats produced by acute administration of PD149163 persisted with no evidence of tolerance after consecutive daily subcutaneous (SC) administration of PD149163 for 16 days (Feifel et al. 2007) . To further investigate whether the APD-like effects of PD149163 exhibit tolerance, we examined the effect of subchronic systemic injection of PD149163 on amphetamine-induced hyperlocomotion.
Materials and methods
Thirty-two male Sprague-Dawley rats (250-300 g at testing, obtained from Harlan Laboratories, San Diego, CA, USA) were housed in pairs under a 12-h:12-h light/ dark schedule (lights on at 7:00 A.M.). All testing occurred during the light phase of the rats' circadian illumination schedule. The test cages were standard cages (42×26 cm) surrounded by grids with eight pairs of infrared beams 4 cm above the bottom of each cage. A computer connected to these grids (San Diego Instruments) measured locomotor activity. Ambulations were defined as the number of times one animal disrupted two different beams in consecutive succession. The principles of animal care were followed, and all procedures are in compliance with the National Institutes of Health Guide for Care and Use of Laboratory Animals (Publication No. 85-23, revised 1985) .
One day before drug testing, rats were placed in locomotor cages for 1 h. Data from the last 30 min (after 30 min of acclimation to cages) was used to assign rats to one of four treatment groups of eight rats matched for locomotor activity. The subchronic pretreatment phase began the next day and consisted of 8 days of daily SC injections. Three groups were administered injections of saline for eight consecutive days. The other group of eight rats received 1 mg/kg PD149163 for eight consecutive days. This dose was based upon the dose-response experiments we have previously performed with PD149163 showing that 1 mg/kg of this drug produced a robust reduction in amphetamine-induced behaviors such as PPI disruption (Feifel et al. 1999 ) and locomotor activation (unpublished data). Twenty minutes before injections, each rat was placed in the test cages to acclimate. After injections, they were put back in the test cages for a 1-h period during which locomotor activity was measured.
Testing occurred on the ninth day. On this day, all rats received two SC injections. After an initial 20 min acclimation period in the locomotor cages, rats were given their first injection of either PD149163 or saline and then replaced in locomotor cages for another 20 min to allow absorption of the first injection. Then each rat received a second injection of either saline or 0.5 mg/kg of amphetamine, after which they were replaced in locomotor cages and locomotor activity was recorded.
Of the three groups that received saline during the subchronic treatment phase, one group received saline/saline on day 9, another group received saline/amphetamine, and another PD149163/amphetamine. The group that received PD149163 during the subchronic pretreatment phase received PD149163/amphetamine on day 9.
All drugs were dissolved in saline (0.9% NaCl) and injected subcutaneously in a volume of 1.0 ml/kg. Amphetamine was obtained from Sigma Chemicals, St. Louis, MO, USA, and PD149163 was generously made available by the NIMH Chemical Synthesis and Drug Supply Program and RTI International, Research Triangle Park, NC, USA.
Locomotor activity data for each rat was analyzed for 30 min after a 10-min initial period (10-40 min after being returned to the cages) to allow for drug absorption. Data from the 24 rats that received saline during the 8-day subchronic treatment period were aggregated. Locomotor data for the first 8 days were analyzed using a two-way analysis of variance (ANOVA) with "day" as the withinsubject factor and "drug treatment" (saline or PD149153) as the between-subject factor. Planned independent samples t tests using the Bonferroni method for multiple comparisons were performed comparing ambulations for both drug groups on each of the 8 days. Locomotor data for day 9 (amphetamine challenge) were analyzed using independent samples t tests with corrections for multiple comparisons. A p value less than 0.05 was considered significant. All statistical analyses were performed using SPSS 11.0 software. Locomotor activity was measured as the number of times spatially adjacent beam pairs were interrupted in consecutive succession as this measure is indicative of ambulations. The number of times a beam was interrupted and not followed by adjacent beam interruption was also analyzed for day 9 (amphetamine challenge), as this measure is indicative of stereotypy.
Results

Subchronic pretreatment
An ANOVA performed on the ambulation data (consecutive beam pair interruption) on the first 8 days of testing revealed no significant main effect of day or drug treatment, but there was a significant day×group interaction, F (7,210)=2.76, p<0.01 (Fig. 1) . Visual inspection of the data comparing rats that received PD149163 to rats that received saline during the 8-day pretreatment phase showed a tendency to produce fewer ambulations in rats treated with PD149163 on the first 2 days, whereas beginning on day 6, PD149163-treated rats exhibited more locomotor activity, and the difference between the two treatments increased until the end of the subchronic pretreatment phase (day 8). Independent samples t tests corrected for multiple comparisons revealed that the PD149163-treated rats exhibited significantly more ambulations than the saline group on day 8, t(30)=−7.08, p<0.001.
Acute amphetamine challenge
Rats pretreated with saline and given amphetamine plus saline on day 9 exhibited significantly increased ambulatory activity (adjacent beam pair interruption) compared to (1) (Fig. 2a) . Furthermore, there was no significant difference in ambulatory activity between the acute or subchronic PD149163 groups. Rats pretreated with saline and given amphetamine plus saline on day 9 exhibited significantly increased nonambulatory type beam interruptions (beam interruption not followed by adjacent beam interruption) compared to saline-only-treated rats [t(9.521)=10.351, p< 0.001]. Rats that received acute or chronic PD149163 in conjunction with amphetamine exhibited reduced nonambulatory beam reductions compared to amphetamine/ saline-treated rats, but in neither case (acute or chronic PD149163) did this reduction reach statistical significance (Fig. 2b) .
Discussion
Our results showed that administration of a single dose and nine consecutive daily doses of PD149163 was able to significantly antagonize the locomotor-activating effects of amphetamine. Because there was no significant difference between the effects of the acute and subchronic administration regimen, we can conclude that there was no tolerance exhibited by PD149163's antiamphetamine effects. Reduction of amphetamine-induced hyperlocomotion is a classic preclinical test of APD potential. To distinguish between reduced locomotor activity due to enhanced amphetamineinduced stereotypy versus inhibition of amphetamine-induced hyperlocomotion, we measured both the number of beam interruptions that were not followed consecutively by interruption of an adjacent beam and the number of consecutive interruptions of spatially adjacent beam pairs. The former is preferentially sensitive to stereotypic movements, whereas the latter is preferentially sensitive to ambulation. Acute and subchronic PD149163 was effectively able to antagonize the amphetamine-induced increase in the total number of ambulation type, but not stereotypy type, beam interruptions, indicating that both acute and subchronic PD149163 produced antagonism of amphetamine's locomotor effects rather than modulating any possible stereotypy-inducing effects of amphetamine.
Another highly used preclinical test of APD efficacy is facilitation of PPI. The lack of tolerance exhibited by PD149163 on amphetamine-induced locomotor activation is consistent with previous findings from our laboratory in which the acute APD-like facilitation of naturally low PPI in Brattleboro rats by acute PD149163 persisted after 16 consecutive daily administrations of PD149163 (Feifel et al. 2007 ). Treatment of psychosis in most cases requires chronic daily use of APDs.
Previous studies have generally shown that established antipsychotics do not display tolerance of their acute ability to inhibit hyperlocomotion produced by amphetamine. For example, the acute reversal of amphetamine-induced hyperlocomotion by two established APDs, haloperidol and olanzapine, were maintained after 24 consecutive days of oral administration (Andersen and Pouzet 2001) . It is interesting to note that another antipsychotic, sertindole, tested at a single dose, did not show such persistence to its acute effects (Andersen and Pouzet 2001) . Similarly, Samaha et al. (2008) demonstrated that haloperidol given by SC injection daily for seven or 12 consecutive days reversed amphetamine-induced hyperlocomotion. However, the same dose administered slowly over the entire day by minipump exhibited tolerance. In the light of these data, the evidence that PD149163 produces robust APD-like effects that do not display tolerance supports the contention that NT1 agonists such as PD149163 are viable putative APDs.
Our findings are more consistent with previous findings that showed that antagonism of amphetamine-and cocaineinduced locomotor activation and apomorphine-induced climbing produced by acute administration of NT69L (Boules et al. 2003 ) and amphetamine-induced hyperlocomotion produced by KK28 (Hadden et al. 2005) persisted after five consecutive daily injections. Our findings stand in contrast to the findings of Hertel et al. (2001) in which it was found that acute effects produced by NT69L on amphetamine-induced hyperlocomotion and conditioned avoidance responding did not persist with repeated administration of that drug.
The reason for the differences between the findings of Hertel's group and the lack of tolerance found by Boules et al. despite that both groups studied NT69L is not clear. Differences in the dosing regimen may have contributed to the discrepant results. A detailed description of these dosing differences can be found in Boules et al. (2003) . However, in general, the studies conducted by Boules et al. used a single daily injection of NT69L at a dose (1 mg/kg) that is in the well-established optimal range for APD-like effects, whereas the studies of Hertel et al. used twice-daily administration of significantly lower doses of NT69L. These two dosing regimens may have produced a distinct activation pattern on NT1 and NT2 receptors because NT69L has relevant affinity for both receptors. In this regard, PD149163 is selective for the NT1 receptor (Petrie et al. 2004 ) and, therefore, provides an optimal pharmacologic tool to examine the role of NT1 receptors and the potential of NT1 selective agonists as putative APDs.
The dosing regimen of PD149163 that we used in this study is more similar to the one used by Boules et al. Therefore, we cannot rule out the possibility that the receptor selectivity of PD149163 plays no role in the persistence exhibited in the APD-like effects of PD149163 and that this is simply a result of the dosing regimen that we used in the current study which is similar to the one we used in our previous study examining its effects on PPI and the one used by Boules et al. However, our main goal was to investigate the APD potential of selective NT1 receptor agonists such as PD149163 and in this regard the single daily dosing regimen used in our studies (and by Boules et al.) is more traditional and more representative of the APD dosing regimen used in clinical practice.
It is interesting to note that while this paper was under review, a paper by Norman et al. (2008) was published examining the subchronic effects of PD149163 on amphetamine-induced hyperlocomotion. Norman et al. found that the ability of an acute infusion of ICV-administered PD149163 to reverse amphetamine-induced hyperlocomotion dissipated after pretreatment with 7 or 21 days of continuous ICV infusion of PD149163 delivered by implanted minipumps. The seemingly contradictory findings of the study of Norman et al. and the one presented in this paper is likely due to the differences in the manner in which PD149163 was administered in both studies. We administered it peripherally, whereas Normal et al. administered this drug centrally. Furthermore, Normal et al. tested how the effects of a single dose of PD149163, centrally administered in a rapid, one-time infusion, was altered after pretreatment with that same daily dose of PD149163 administered continuously every 24 h for 7 or 21 days by minipump. Thus, in that study, the acute administration was different than the subchronic and chronic pretreatments, whereas, in our study, all administrations of PD149163 were done in a similar manner. It is not clear whether the dose of PD149163 tested by Normal et al. delivered slowly over 24 h would produce APD-like reversal of amphetamine-induced hyperlocomotion because this was never tested in their study. There is evidence that chronic infusion of a drug dose continuously over 24 h produces very different pharmacokinetic and pharmacodynamic effects compared to administration of that same dose in a rapid fashion. For example, a dose of haloperidol given peripherally over 24 h continuously by minipump for 21 days lost its acute efficacy in two animal models of APD-like effects, amphetamine-induced hyperlocomotion, and conditioned avoidance response, whereas when administered for the same period by daily SC injection, it did not (Samaha et al. 2008) . Samaha et al. (2008) and Andersen and Pouzet (2001) found a similar loss of the acute efficacy for several established APDs including haloperidol in another animal model of APD-like effects, disruption of PPI, when these APD drugs were administered continuously by osmotic minipump. Thus, the findings of Norman et al. must be considered in the context of these findings. While there are differences between rats and humans in the pharmacokinetics of acute administration of APDs (Kapur et al. 2003) , we believe that our methodology, daily rapid administration of doses peripherally, is a better model of the common clinical administration of APDs in humans than the continuous central slow infusion, followed by the rapid central infusion method used by Norman et al. In fact, the most compelling proof of this contention is the fact that established APDs, whose therapeutic effects do not demonstrate tolerance with chronic use in humans, exhibit tolerance when delivered to rodents by the method of administration used by Norman et al., whereas they do not do so when administered by the method that we have employed.
An unexpected finding of this study was that subchronic administration of PD149163 resulted in stimulation of spontaneous locomotor activity, an effect not seen with acute administration. This difference between the effects of acute and subchronic PD149163 was the result of locomotor activity decreasing from the first to the last day of testing in the saline-treated but not PD149163-treated animals. Therefore, the effect of PD149163 may have been to inhibit habituation to the locomotor cage over time rather than to stimulate locomotor activity. To address this possibility, we analyzed the locomotor data from the 20-min period after rats were placed into locomotor cages each day for acclimation before receiving drug injections. Salinetreated rats decreased their spontaneous locomotor activity during this pretreatment period by 58.3% from day 1 to day 8, which was comparable to the degree of habituation seen by PD149163-treated rats (65.3%) across this period. These data suggest that the increase in locomotor activity seen in subchronic PD149163-treated rats is due to stimulation of their activity rather than an inhibition of habituation to the locomotor cages.
The exact mechanism underlying this locomotor stimulatory effect is not known, but because NT1 receptors are known to regulate mesolimbic dopamine function, a neural system that mediates locomotor activity, this phenomenon may be produced via the action of this NT agonist on mesolimbic DA function. Acute administration of NT or NT receptor agonists are known to inhibit the effects of dopamine agonists, presumably via downregulation of D2 receptor affinity for dopamine (Fuxe et al. 1992) . It is possible that with repeated activation of the NT1 receptor, mesolimbic dopamine function overcompensates, for example, by upregulating D2 receptor density or affinity. It is very interesting to note that the activation produced by subchronic administration of PD149163 on spontaneous locomotor activity did not preclude the ability of that treatment regimen to antagonize the hyperlocomotion induced by amphetamine. This result is analogous to the expected effects of partial D2 receptor agonists, which are able to increase transmission through that receptor under conditions of low ambient neurotransmission and decrease transmission through that receptor under abnormally high existing levels of activity such as occurs with amphetamine administration. This putative phenomenon warrants further investigation, for example, by examining possible differences in changes in dopamine release and D2 receptor density induced by acute versus subchronic administration of PD149163.
